Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)